 - Chronic HCV infection must be documented by positive anti HCV antibody using a third generation enzyme immunoassay EIA and persistent detection of HCV RNA in the blood for at least 6 months. Subjects must be infected with HCV genotype 1 line probe assay; INNO-LiPA HCV II, Innogenetics and may be treatment-naïve or treatment-experienced treatment experienced specifically means prior treatment with interferon, standard or pegylated, with or without ribavirin with therapy stopped 6 months prior to screening. In addition, eligible subjects must have ALT and AST 5 x upper limit of normal ULN, plasma HCV RNA 5 log10 IUmL, and have no clinical or laboratory evidence of hepatic decompensation for inclusion must have platelets 100,000mm3, total bilirubin 1.5 x ULN, prothrombin time 1.5 x ULN, or albumin 3.0 gdL for inclusion. Women are eligible if not pregnant or breast-feeding. Women of childbearing potential i.e., not surgically sterile or confirmed post menopausal must have confirmed negative pregnancy tests. All subjects must practice a medically acceptable form of contraception described in Section 7.2.1. 